PlanMySupps

Cover Block

PUBLIC

Attribute	Details
Company	PlanMySupps
Tagline	Personalized, evidence-based supplement plans and infrastructure for supplement protocols. [PlanMySupps, retrieved 2024]
Headquarters	Paris, France
Founded	2021
Stage	Pre-Seed
Business Model	Direct-to-Consumer (DTC)
Industry	Healthtech
Technology	Software (Non-AI)
Geography	Global / Remote-First
Growth Profile	Venture Scale
Founding Team	Co-Founders (2)
Funding Label	Pre-Seed

Links

PUBLIC

• Website: https://planmysupps.com/
• LinkedIn: https://www.linkedin.com/in/jessicalytle/

PlanMySupps maintains a minimal public footprint. The company website is the primary source for product information, while the LinkedIn profile of co-founder Jess Lytle provides the most detailed public view of the founding team and the company's positioning. No other official social media accounts, app store listings, or GitHub repositories are confirmed from available sources.

PUBLIC PlanMySupps is a Paris-based healthtech startup building software to generate personalized supplement protocols, a proposition that stands out for its explicit grounding in clinical evidence rather than wellness marketing. Founded in 2021 by Jess Lytle and Cristina Gall, the company positions its product as infrastructure for evidence-based supplement plans, a wedge into a market often characterized by generic recommendations [PlanMySupps, retrieved 2024]. The founding team's backgrounds in nutritional epidemiology and supplement coaching provide a credible, if narrow, foundation for the product's scientific positioning [LinkedIn, retrieved 2024] [RocketReach, retrieved 2024]. As of 2025, the company shows no public record of institutional funding, named enterprise customers, or major media coverage, indicating a very early, likely bootstrapped stage [Perplexity Sonar Pro Brief, retrieved 2024]. The next 12 to 18 months will be critical for demonstrating whether the evidence-based protocol engine can secure initial paying customers and forge the data partnerships necessary to validate its technical claims.

Data Accuracy: YELLOW -- Core product claims from company site; team backgrounds from professional profiles; absence of funding/customers corroborated by search.

Taxonomy Snapshot

Axis	Value
Stage	Pre-Seed
Business Model	Direct-to-Consumer (DTC)
Industry / Vertical	Healthtech
Technology Type	Software (Non-AI)
Geography	Global / Remote-First
Growth Profile	Venture Scale
Founding Team	Co-Founders (2)

Company Overview

PUBLIC

PlanMySupps was founded in 2021 in Paris, France, as a remote-first healthtech venture [Crunchbase, 2026]. The company’s public identity is anchored by its two co-founders, Jess Lytle and Cristina Gall, who have structured the business around a direct-to-consumer software model rather than supplement retail [PlanMySupps, 2024].

Key operational milestones are not detailed in public filings or press. The company’s primary public milestone remains the launch of its website and product concept, which describes a protocol-generation engine for personalized supplement plans [PlanMySupps, 2024]. There is no public record of institutional funding rounds, major customer announcements, or partnership disclosures as of 2024-2025 [Perplexity Sonar Pro Brief, 2024].

The founding team’s academic and professional backgrounds provide the core narrative for the company’s evidence-based positioning. Jess Lytle holds an MSc in Nutritional Epidemiology from Harvard, a credential directly cited in the product’s framing [LinkedIn, 2024]. Cristina Gall, identified as CEO, is a Harvard-trained supplement coach, bringing practical experience from prior coaching work [Supplement Coaching, 2026] [RocketReach, 2024]. This combination of scientific methodology and applied coaching informs the company’s stated wedge in the market.

Data Accuracy: YELLOW -- Company founding details are confirmed via Crunchbase and founder profiles; operational milestones and entity structure are not publicly documented.

Product and Technology

MIXED The product is a software layer for supplement decision-making, not a direct seller of pills. According to its website, PlanMySupps provides personalized, evidence-based supplement plans and the infrastructure for building those protocols [PlanMySupps, retrieved 2024]. The language frames the service as a protocol-generation engine, a data and decision layer that sits between a user and the supplements they might purchase elsewhere.

Its differentiation hinges on the application of nutritional epidemiology to filter recommendations. The company's public positioning repeatedly emphasizes an evidence-based methodology, a claim anchored by co-founder Jess Lytle's academic background in nutritional epidemiology from Harvard [LinkedIn, retrieved 2024]. The product appears to generate individualized regimens by taking user inputs and structuring them against a database of clinical evidence, though the specific algorithms, data sources, and validation processes are not documented on the public site [Perplexity Sonar Pro Brief, retrieved 2024].

As a direct-to-consumer software product, the current user experience is consumer-facing. The website is pitched to individuals seeking a scientifically-grounded supplement plan, with no visible B2B pricing, provider dashboards, or language targeting clinics or coaches on its public pages [Perplexity Sonar Pro Brief, retrieved 2024]. The technical stack is not publicly disclosed, and there is no mention of regulatory clearances, such as FDA approvals for software as a medical device, in available materials.

Data Accuracy: YELLOW -- Product claims are sourced from the company website; technical and operational details are not independently verified.

Market Research

PUBLIC The market for personalized health interventions, particularly in supplements, is expanding as consumers increasingly seek data-driven alternatives to generic over-the-counter products. This shift is driven by a confluence of scientific interest, consumer behavior changes, and technological enablement, though it operates within a complex and lightly regulated landscape.

Demand is anchored in a growing body of research linking specific micronutrients to health outcomes, which has elevated consumer expectations. The public-facing narrative from PlanMySupps and its competitors emphasizes "evidence-based" recommendations, a direct response to consumer skepticism towards the unsubstantiated claims common in the broader wellness industry [PlanMySupps, retrieved 2024]. This is coupled with a broader tailwind of personalized health, where consumers, accustomed to customization in other digital services, now expect similar personalization for their physical well-being. The direct-to-consumer model lowers the barrier to access, allowing individuals to bypass traditional healthcare gatekeepers, though this also introduces questions about oversight and clinical validation.

Adjacent and substitute markets are significant. The most direct substitute is the traditional retail supplement aisle, a massive but undifferentiated market. More sophisticated adjacent markets include telehealth platforms that integrate supplement recommendations into broader care plans, and functional medicine practices that offer highly personalized protocols but at a much higher cost and with direct clinician involvement. The company's positioning as "infrastructure" suggests a potential bridge between these clinical services and the mass market, but that role is not yet proven.

Regulatory and macro forces present both a barrier and a potential moat. In the United States and Europe, dietary supplements are largely regulated under food safety frameworks rather than pharmaceutical pre-approval processes. This allows for faster product iteration but creates a trust deficit, as consumers cannot rely on regulatory vetting for efficacy. A company building a reputation on clinical evidence could differentiate itself, but it also assumes the liability of interpreting complex scientific literature for a general audience. Macroeconomic pressures on consumer discretionary spending could also impact demand for premium personalized services, making clear demonstrable value a critical success factor.

Data Accuracy: YELLOW -- Market sizing and driver analysis is inferred from adjacent company positioning and industry commentary; no third-party market report specific to PlanMySupps's model is publicly cited.

Competitive Landscape

MIXED PlanMySupps enters a market where established players have built consumer trust through brand recognition and direct product fulfillment, positioning itself as a software layer that prioritizes evidence-based protocol generation over supplement sales.

Company	Positioning	Stage / Funding	Notable Differentiator	Source
PlanMySupps	Software for personalized, evidence-based supplement protocol generation.	Pre-Seed; no public funding rounds.	Focus on nutritional epidemiology and a protocol-generation engine, not direct e-commerce.	[PlanMySupps, retrieved 2024]
Rootine	Direct-to-consumer personalized vitamins based on blood test data.	Venture-backed; $10M Series A in 2021.	Uses at-home blood testing to tailor micronutrient formulas.	[Crunchbase, 2021]
Persona / Care/of	DTC personalized vitamin subscription services.	Persona acquired by Nestlé; Care/of raised $29M.	Strong brand recognition and scaled subscription models.	[Crunchbase, 2019]
Hormonify	Platform focused on hormone-balancing supplement protocols.	Early-stage; specific funding not public.	Niche focus on hormonal health for a specific demographic.	[Hormonify, retrieved 2026]

Competition in the personalized supplement space is segmented by the depth of personalization and the underlying business model. On one side are scaled DTC subscription brands like Persona and Care/of, which use lifestyle quizzes to recommend pre-formulated blends from their own inventory. Their advantage is in brand ubiquity and efficient fulfillment. A more technical segment includes companies like Rootine, which incorporates biomarker data from blood tests to create bespoke formulas, competing on a claim of deeper scientific rigor. PlanMySupps sits apart by not selling physical products, instead offering the decision-making infrastructure. This places it adjacent to coaching platforms and clinical tools used by practitioners, a segment where it currently lacks named partnerships.

The company's stated edge is its foundational emphasis on nutritional epidemiology and clinical evidence, as articulated by co-founder Jess Lytle's academic background [LinkedIn, retrieved 2024]. This positions the protocol engine as a filter against the noise of the unregulated supplement market, a potential trust signal for evidence-oriented consumers. This edge is perishable, however, as it relies on the perceived authority of its methodology rather than patented technology or exclusive data partnerships. Without public documentation of its algorithms or data sources, the defensibility of this edge remains an open question [Perplexity Sonar Pro Brief, retrieved 2024].

PlanMySupps is most exposed in distribution and validation. It does not own a supplement supply chain or a diagnostic channel like Rootine's blood tests. Its pure software model depends on users trusting its recommendations enough to source products elsewhere, introducing friction. Furthermore, the absence of disclosed B2B features leaves it vulnerable to integrated platforms like Fullscript, which combine practitioner software with a vast supplement dispensary [Fullscript, retrieved 2026]. A competitor with similar evidence-based claims but deeper integration into a telehealth or clinic workflow could quickly nullify PlanMySupps' current positioning.

The most plausible 18-month scenario hinges on whether PlanMySupps can transition from a consumer-facing tool to an embedded infrastructure layer. If it successfully partners with telehealth providers or functional medicine clinics, it could become a white-label protocol engine, a "winner if integrated." In that case, a DTC-only competitor like Care/of, which is less focused on B2B enablement, could be a "loser if channel shifts." Conversely, if PlanMySupps remains a standalone DTC app without a clear path to monetization or partnership, it risks being overshadowed by better-funded incumbents that can simply add more sophisticated quiz logic to their existing models.

Data Accuracy: YELLOW -- Competitor profiles and funding stages are confirmed via public databases and company sites; PlanMySupps' differentiation is sourced from its own materials without third-party validation.

Opportunity

PUBLIC If PlanMySupps can successfully productize its evidence-based protocol engine, the opportunity lies in becoming the trusted decision layer for a global supplements market that has long operated on anecdote and marketing.

The headline opportunity is the creation of a category-defining platform for supplement personalization, one that could shift consumer and practitioner behavior away from generic recommendations. The company's positioning as "infrastructure" for protocols, rather than a simple e-commerce brand, suggests a wedge into becoming the default software for generating and managing supplement regimens [PlanMySupps, retrieved 2024]. This outcome is reachable because the core differentiator,leveraging nutritional epidemiology to filter recommendations,is directly tied to a founder's credentialed expertise, a tangible asset in a trust-sensitive market [LinkedIn, retrieved 2024]. Success would mean PlanMySupps defines the standard for how evidence is applied to supplement decisions, a role currently unfilled by any single dominant player.

Growth could follow several distinct paths, each with a plausible catalyst based on observable market dynamics.

Scenario	What happens	Catalyst	Why it's plausible
B2B White-Label Engine	The protocol-generation software is licensed to telehealth platforms, functional medicine clinics, and wellness brands.	A partnership with a major practitioner-focused supplement distributor (e.g., Fullscript) or a digital health platform seeking to add supplement personalization.	The market already shows demand for using lab data to guide supplement plans, and established platforms seek to add personalized services [Fullscript, retrieved 2026]. A software-as-infrastructure model aligns with this integration need.
Consumer Subscription Scale	The direct-to-consumer app becomes a must-have for health-optimizing individuals, scaling to millions of users.	The launch of a mobile app that simplifies protocol adherence and tracking, coupled with content marketing that establishes category authority.	Consumer demand for personalized, science-backed health guidance is a durable trend; successful DTC health apps demonstrate the model [Crunchbase, retrieved 2026]. The founders' coaching and science background provides a foundation for authority-building content.
Regulatory & Standard-Setting	The company's evidence-based methodology becomes a de facto standard, leading to B2G contracts or mandatory use in certain care pathways.	Publication of peer-reviewed research validating the protocol engine's outcomes, attracting institutional and governmental interest.	Public health entities are increasingly focused on evidence-based approaches to nutrition and supplementation; a Harvard-linked, research-grounded methodology could attract such partnerships [Medgevity Health, retrieved 2026].

Compounding for PlanMySupps would manifest as a data and trust flywheel. Each user interaction generates data on supplement responses and health outcomes, which could be used to refine the underlying algorithm, making recommendations more accurate over time. This creates a classic data moat: a more used product becomes a smarter product, which in turn attracts more users and deepens engagement. Furthermore, every successful protocol builds trust, not just in the software but in the broader concept of evidence-based supplementation. This trust could lower customer acquisition costs and increase lifetime value, as users become less likely to churn to less rigorous alternatives. While no public data confirms this flywheel is in motion, the product's designed function as a protocol-generation engine is the necessary precursor.

The size of the win can be framed by looking at comparable models. Rootine, a competitor in personalized vitamins, has raised venture funding and established a brand in the premium DTC segment. In a successful B2B software scenario, PlanMySupps could aim for valuations similar to other vertical SaaS companies providing critical workflow tools to healthcare practitioners, which often trade at significant revenue multiples. If the consumer subscription scenario prevails, the outcome could resemble a specialized health subscription business at scale. These are illustrative scenarios, not forecasts, but they map the potential value creation if the company executes on its infrastructure thesis and captures a meaningful portion of the decision-making process in a multi-billion dollar global market.

Data Accuracy: YELLOW -- Opportunity analysis is based on company positioning and market dynamics; specific growth catalysts and comparables are inferred from adjacent market evidence.

Sources

PUBLIC

1. [PlanMySupps, retrieved 2024] Personalized, Evidence-Based Supplement Plans | https://planmysupps.com/

2. [LinkedIn, retrieved 2024] Jess (Jessica) Lytle's LinkedIn Profile | https://www.linkedin.com/in/jessicalytle/

3. [RocketReach, retrieved 2024] Cristina Gall's RocketReach Profile | https://rocketreach.co/cristina-gall_b511394348572533

4. [Perplexity Sonar Pro Brief, retrieved 2024] Perplexity Sonar Pro Brief | https://www.perplexity.ai/pro/sonar

5. [Crunchbase, 2026] List of top Paris Startups Founded in 2021 | https://www.crunchbase.com/hub/paris-startups-founded-in-2021

6. [Supplement Coaching, retrieved 2026] About Cristina Gall, Harvard-Trained Supplement Coach | https://www.supplementcoaching.com/about-cristina

7. [Hormonify, retrieved 2026] Benefits of a Personalized Supplement Protocol | https://hormonify.com/benefits-of-a-personalized-supplement-protocol/

8. [Fullscript, retrieved 2026] Using Lab Data to Guide Personalized Supplement Plans | https://fullscript.com/blog/steps-to-personalize-supplement-recommendations

9. [Medgevity Health, retrieved 2026] Personalized Supplement Strategies | https://www.medgevityhealth.com/home-pages/personalized-supplement-strategies

10. [Crunchbase, 2021] Rootine Funding Round | https://www.crunchbase.com/

11. [Crunchbase, 2019] Persona / Care/of Funding | https://www.crunchbase.com/

12. [Crunchbase, retrieved 2026] Consumer Health App Market | https://www.crunchbase.com/